CRISPR Therapeutics, Sirius Initiate Phase 2 European Trial of FXI Inhibitor SRSD107 for VTE Prevention

CRISPR Therapeutics and Sirius Therapeutics have initiated a Phase 2 clinical trial for SRSD107, a novel siRNA therapy designed to inhibit Factor XI, aiming to prevent venous thromboembolism (VTE) in patients undergoing total knee arthroplasty. SRSD107 has shown promising results in Phase 1 trials with sustained reductions in Factor XI levels and prolonged anticoagulant effects, potentially enabling infrequent dosing and lowering bleeding risks compared to current anticoagulants. This ongoing global study will evaluate SRSD107's safety, efficacy, and pharmacological profile to establish its clinical utility in thrombotic disorders. Additionally, CRISPR Medicine News highlights other gene editing clinical trials for rare diseases such as familial chylomicronemia syndrome and beta-thalassemia, underscoring the expanding application of gene-based therapies. These developments reflect significant progress in leveraging gene editing and RNA interference technologies to address challenging medical conditions with unmet needs.